START also provides quality preclinical research services to the pharmaceutical industry in order to accelerate the development of new oncology agents.

The team can screen hundreds of experimental compounds each year using both cell and tumor-based assays. Our experienced researchers provide support and assistance in lead compound identification and proof of principle studies. In addition, our experience with standard agents along with an extensive database of efficacy and toxicity profiles for approved chemotherapeutics allows detailed evaluation of novel agents in combination with standard therapeutic regimens. A number of experimental therapeutics currently undergoing clinical investigation was first identified in preclinical efficacy screens performed at START. Moreover, we have assisted past sponsors in the development of some of the most important oncology drugs being utilized in the clinic today.

START is organized and managed along standard business lines.  We understand timelines and cost control, as well as the importance of accurate, quality assured data, dedicated investigators, and proprietary issues such as protection of confidential information and intellectual property rights.